Zhang SY. Navigating new horizons in inflammatory bowel disease: Integrative approaches and innovations. World J Gastroenterol 2024; 30(41): 4411-4416 [PMID: 39534414 DOI: 10.3748/wjg.v30.i41.4411]
Corresponding Author of This Article
Shi-Yan Zhang, MD, Director, Department of Clinical Laboratory, Fuding Hospital, Fujian University of Traditional Chinese Medicine, No. 120 South Road of Old City, Fuding 355200, Fujian Province, China. myebox@139.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Nov 7, 2024; 30(41): 4411-4416 Published online Nov 7, 2024. doi: 10.3748/wjg.v30.i41.4411
Navigating new horizons in inflammatory bowel disease: Integrative approaches and innovations
Shi-Yan Zhang
Shi-Yan Zhang, Department of Clinical Laboratory, Fuding Hospital, Fujian University of Traditional Chinese Medicine, Fuding 355200, Fujian Province, China
Author contributions: Zhang SY wrote and edited the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shi-Yan Zhang, MD, Director, Department of Clinical Laboratory, Fuding Hospital, Fujian University of Traditional Chinese Medicine, No. 120 South Road of Old City, Fuding 355200, Fujian Province, China. myebox@139.com
Received: April 27, 2024 Revised: September 26, 2024 Accepted: October 11, 2024 Published online: November 7, 2024 Processing time: 179 Days and 2.6 Hours
Abstract
This editorial offers an updated synthesis of the major advancements in the management and treatment of inflammatory bowel disease (IBD), as documented in the World Journal of Gastroenterology between 2023 and early 2024. This editorial explores substantial developments across key research areas, such as intestinal microecology, computational drug discovery, dual biologic therapy, telemedicine, and the integration of lifestyle changes into patient care. Furthermore, the discussion of emerging topics, including bowel preparation in colonoscopy, the impact of the coronavirus disease 2019 pandemic, and the intersection between IBD and mental health, reflects a shift toward a more holistic approach to IBD research. By integrating these diverse areas of research, this editorial seeks to promote a holistic and multidisciplinary approach to IBD treatment, combining emerging technologies, personalized medicine, and conventional therapies to improve patient outcomes.
Core Tip: This editorial encapsulates pivotal research and breakthroughs in inflammatory bowel disease (IBD) treatment, suggesting a comprehensive and integrated approach. It highlights intestinal microecology enhancement, the application of computational methods for drug discovery, dual biologic therapy use, and the integration of telemedicine. Additionally, a discussion of emerging concerns, such as the effects of the coronavirus disease 2019 pandemic, mental health challenges, and bowel preparation strategies in IBD care, illustrates the importance of addressing these interconnected aspects for holistic patient management. There remains a necessity for collaborative, innovative treatment strategies that leverage cross-disciplinary insights to advance care in IBD patients.
